A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Inclusion Criteria:

• Participant is ≥18 years old at the time of written informed consent and ishospitalized.

• Participant has provided the written informed consent. If a participant is unable toprovide written informed consent due to their medical condition, the participant'slegally authorized representative may consent on behalf of the participant, or thedecision can be made according to the procedure permitted by local law andinstitutional standard operating procedures (SOPs).

• Participant has a proven or strongly suspected diagnosis of an infection caused bysusceptible ABC isolates, based on investigator's clinical judgment.

• Participant initiates treatment with SUL-DUR per routine clinical care. Participantswho receive SUL-DUR within 24 hours prior to enrollment are also eligible toparticipate. The decision to treat the participant with SUL-DUR is made prior to andindependently of study participation.

• The participant has an expected survival of >48 hours at the time of writteninformed consent.

Exclusion Criteria:

• A history of significant hypersensitivity or allergic reaction to any β-lactam, orany contraindication to the use of β-lactam antibiotics